QT Imaging Holdings, Inc. (QTI)

QT Imaging Holdings makes machines that take pictures inside the human body using sound waves. The company was founded in 2012 and went public in March 2024 after a merger with a SPAC (a special-purpose acquisition company). The ticker is QTI on Nasdaq, and QTIWW represents warrants trading over-the-counter. The company is based in Novato, California.

What the company does

QT Imaging builds an ultrasound machine called the QT Breast Scanner. Ultrasound uses sound waves bounced through tissue to create a picture of what is inside. Most people know ultrasound from pregnancy—the sonogram that shows a fetus. QT’s machine does the same thing but is designed specifically to image breast tissue and detect cancer.

Traditional mammography (the standard test for breast cancer) uses X-rays. Mammography is effective, but it misses tumors in women with dense breast tissue, and it can sometimes flag benign lumps as suspicious, leading to unnecessary biopsies. Ultrasound is better at seeing through dense tissue, but conventional handheld ultrasound requires a skilled technician and produces images that are slow to acquire and subjective to interpret.

QT’s answer is a dedicated breast ultrasound system that is faster, more standardized, and produces images that are easier for radiologists to read. The QT Breast Scanner combines hardware and software. The hardware is a bed or chair that positions a patient and holds a scanning transducer against the breast. The software, called QTviewer, reconstructs the ultrasound signals into a three-dimensional or volumetric image of the breast tissue.

Why this matters

Breast cancer is common and lethal if not caught early. In the United States, about one in eight women will be diagnosed with invasive breast cancer at some point in her life. Detecting cancer early, when tumors are small and have not spread, dramatically improves treatment outcomes and survival.

The problem is that not all women are equally easy to screen. Mammography works well in women with non-dense breast tissue but is less effective in women with fibroglandular (dense) breast tissue. Radiologists often recommend supplemental ultrasound for these women, but conventional ultrasound is operator-dependent, time-consuming, and uncomfortable for the patient. A standardized, automated ultrasound system that produces consistent, high-quality images could improve screening for millions of women and reduce unnecessary biopsies.

QT is betting that hospitals and imaging centers will buy the QT Breast Scanner as an alternative or supplement to mammography, particularly for breast cancer screening in women with dense breast tissue.

How QT makes money

The company sells the QT Breast Scanner hardware to hospitals, outpatient imaging centers, and breast clinics. The sale price of the hardware is a one-time fee. Once installed, the machine requires maintenance, software updates, and training, which generate ongoing service and licensing revenue. The QTviewer software can be licensed separately or bundled with the hardware.

The business model is typical for medical device companies. A customer buys a machine, the company ships it, installs it, and trains the customer’s staff. Over time, the company collects service fees and sells supplies (ultrasound gel, cleaning materials, replacement parts). The machine also generates data about breast tissue, which could eventually be used to train artificial-intelligence algorithms to interpret images more accurately—a future value stream.

The competitive landscape and moat

QT is not the only company working on breast ultrasound. Established medical device companies like GE, Philips, and Siemens have conventional ultrasound systems that can be adapted for breast imaging. Specialized companies like Delphinus Medical Technologies (which uses microwave imaging rather than ultrasound) are pursuing competing technologies.

QT’s advantage is focus and specialization. The company built a system designed from the ground up for breast imaging, not adapted from a general-purpose ultrasound platform. That focus means the hardware, software, and workflow are optimized for the specific clinical problem.

The real moat, if one exists, comes from clinical evidence and regulatory approval. If QT can demonstrate through clinical trials that the Breast Scanner detects cancers that mammography misses, and if the images are reproducible and easy for radiologists to interpret, then insurance companies will pay for the scans. Once insurance covers it, hospitals will have a financial reason to buy. That clinical evidence is not yet established at the scale needed to drive broad adoption, and generating it takes years and millions of dollars.

Regulatory approval is another layer. The device has cleared the FDA (the machine is legal to sell in the United States), but that is a lower bar than demonstrating clinical benefit. Reimbursement from Medicare and private insurance requires clinical evidence that the device improves outcomes—detects more cancers, reduces unnecessary biopsies, improves patient survival—at a cost that insurance is willing to pay. QT has not yet proven that.

The risks and unknowns

The biggest risk is that the market does not materialize. If hospitals decide that conventional ultrasound is good enough, or if they stick with mammography and avoid supplemental imaging, QT’s system becomes a niche product. Adoption also depends on reimbursement. If Medicare and private insurers do not pay for QT Breast Scanner scans, hospitals have no financial incentive to buy.

A second risk is competition from larger device makers. Philips or GE could invest in breast ultrasound, leverage their existing relationships with hospitals, and capture the market. QT is small and will always have less capital than giants.

Clinical evidence is a third risk. If clinical trials show that the QT Breast Scanner does not meaningfully improve cancer detection or reduces unnecessary biopsies less than expected, the case for adoption collapses.

How to research QT Imaging as an investment

Read the 10-K filing (SEC CIK 0001844505) to understand the current customer base (how many hospitals have bought the machine?), revenue per installed system, and the timeline for reimbursement discussions with Medicare and private insurance.

Watch the company’s announcements about clinical studies. Are researchers at major hospitals evaluating the QT Breast Scanner? Are those studies being published in medical journals? Positive clinical data is the gate that opens the market.

Track the installed base—how many QT Breast Scanners are in use? If the number is growing and the average revenue per installed system is increasing (through service contracts and software), the company is building sustainable business. If installations are stalling or customers are not renewing maintenance contracts, the adoption is not happening.

Finally, pay attention to regulatory and reimbursement news. Any indication that Medicare is considering coverage, or that private insurers are beginning to reimburse scans with the QT Breast Scanner, is a material catalyst. Conversely, any hint that insurance companies view supplemental breast ultrasound as unnecessary or low-value would be a major headwind.